Pack Health partners with California university for pilot program on myeloma

Pack Health is participating in a pilot study with the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. For Pack Health, it's the latest in a series of notable partnerships for the Birmingham-based firm. The study intends to use digital coaching to support individuals with multiple myeloma who are undergoing stem cell transplantation.  “We are excited to expand the role of digital coaching to this unique patient population for whom the transplantation…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

We determined the impact of bone marrow fibrosis (BMF) on the clinical outcomes of newly diagnosed multiple myeloma patients in the current era of myeloma therapy. We found that BMF is common in myeloma and MM patients with BMF (particularly those with extensive BMF) have a poorer prognosis even when treated with immunomodulatory agents and proteasome inhibitors. AbstractWe determined the impact of bone marrow fibrosis (BMF) on the clinical outcomes of newly diagnosed multiple myeloma (NDMM) patients in the current era of myeloma therapy. A total of 393 MM patients were included in the final analysis. The median followup w...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract INTRODUCTION: Duration of first remission is important for the survival of multiple myeloma (MM) patients. METHODS: From the CoMMpass study (NCT01454297), 926 newly diagnosed MM patients, characterized by next-generation sequencing, were analyzed to evaluate those who experienced early progressive disease (PD) (time to progression, TTP≤18 months). RESULTS: After a median follow-up of 39 months, early PD was detected in 191/926 (20.6%) patients, 228/926 (24.6%) patients had late PD (TTP>18 months), while 507/926 (54.8%) did not have PD at the current follow-up. Compared to Late PD patients,...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This study provides a real-world picture of first relapsed myeloma and highlights the prognostic importance of the treatment sequence.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionPom ‐PAD‐Dara represents a promising multiagent regimen in heavily pretreated RRMM patients with high ORR and an acceptable safety profile.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
AbstractInfection is associated with great morbidity and mortality in patients with multiple myeloma (MM), but evidence for invasive fungal infections (IFIs) is lacking. We aimed to investigate risk factors for IFI in MM patients and to determine its impact on patients ’ survival. We retrospectively analyzed MM patients at Taipei Veterans General Hospital in Taiwan between January 2002 and October 2018. MM was diagnosed according to the International Myeloma Working Group criteria. IFI was defined according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. All risk factor...
Source: Annals of Hematology - Category: Hematology Source Type: research
Conclusion: These results showed 212Pb-daratumumab to have efficacy in xenografted mice, with significant tumor regression and increased survival. This study highlights the potency of α-RIT in MM treatment.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Source Type: research
Patients were categorized as HIV+ and HIV −, and treatment categorized as systemic therapy (SysT), hematopoietic stem cell transplantation (HCT), and no systemic therapy reported (noSysT). Among HIV+, the positive predictors for SysT were insurance and higher income while female sex and minority racial status were negative predictors. The survival improved with SysT or HCT but were worse than HIV− patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Data from National Cancer Database (NCDB) was analyzed for predictors of treatment and survival for lymphoma patients with HIV. Patients were categorized as HIV+ and HIV-, and first line treatment categorized as systemic therapy (SysT), hematopoietic stem cell transplant (HCT) and no systemic therapy reported (no-SysT). Among HIV+, the positive predictors for SysT were insurance and higher income while female sex and minority racial status were negative predictors. The survival outcomes improved with SysT or HCT but were worse than HIV- patients. Individual patient characteristics and complications should be a focus for future research.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
poulou-Strauss There is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used 18F-fluorodeoxyglucose (18F-FDG). Sodium fluoride (18F-NaF) is a highly sensitive tracer of bone reconstruction, evolving as an important imaging agent for the assessment of malignant bone diseases. We attempted to investigate for the first time the prognostic significance of 18F-NaF PET/CT in newly diagnosed, symptomatic MM patients planned for autologous stem cell transplantation (ASCT). Forty-seven patients underwent d...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Objectives: Cancer affects up to 20% of critically ill patients, and sepsis is one of the leading reasons for ICU admission in this setting. Early signals suggested that survival might be increasing in this population. However, confirmation studies have been lacking. The goal of this study was to assess trends in survival rates over time in cancer patients admitted to the ICU for sepsis or septic shock over the last 2 decades. Data Source: Seven European ICUs. Study Selection: A hierarchical model taking into account the year of admission and the source dataset as random variables was used to identify risk factors ...
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Clinical Investigations Source Type: research
More News: Cancer | Cancer & Oncology | Health Management | Information Technology | Myeloma | Partnerships | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | Transplants